BioCentury
ARTICLE | Clinical News

SB-061: Completed Ph I/IIa enrollment

November 17, 2016 2:32 PM UTC

Symic and Nordic completed enrollment of 147 patients in the double-blind, placebo-controlled, European Phase I/IIa MODIFY-OA trial evaluating 2 intra-articular injections of SB-061. Last year, Symic ...

BCIQ Company Profiles

Nordic Bioscience A/S